To print: Select File and then Print from your browser's menu

Title: Teriparatide Approved in Canada for Steroid-Induced Osteoporosis

"Teriparatide Approved in Canada for Steroid-Induced Osteoporosis"

TORONTO -- August 21, 2008 -- Teriparatide (rDNA origin [Forteo]) injection] has been approved by Health Canada for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women who are at high risk for bone fracture. The approval of teriparatide is based on a 36-month, double-blind, active comparator-controlled trial published in the[ New England Journal of Medicine.

The study found that at 18 months of therapy, teriparatide significantly increased lumbar spine bone mineral density (BMD) from baseline (7.2%) compared with alendronate sodium (Fosamax [3.4%]).

This new indication provides patients with a new treatment option to reduce their risk of bone fracture and bone loss related to glucocorticoid therapy.

SOURCE: Eli Lilly Canada Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.